SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Mirvie, a company bringing a personalized, predictive, and preventive approach to pregnancy complications, today announced the company was selected to present new research demonstrating the ability of the Mirvie RNA platform to predict the risk of severe fetal growth restriction in pregnancy. The abstract, “Prediction of severely small-for-gestational-age infants using a novel cell-free RNA model,” will be presented on Thursday, January 30, 2025 9:1